Clinical Report: Reintroduction of ruxolitinib following toxicity from momelotinib
Overview
This case study presents the reintroduction of low-dose ruxolitinib in a 74-year-old female with secondary myelofibrosis after experiencing toxicity from momelotinib. The patient achieved anemia control.
Background
Myelofibrosis is a chronic myeloproliferative neoplasm that impacts patient quality of life due to symptoms and complications such as anemia. The use of Janus kinase inhibitors (JAKi) like ruxolitinib and momelotinib has become standard in managing this condition, yet treatment-related toxicities can complicate therapy.
Data Highlights
No numerical data or trial data was presented in the article.
Key Findings
A 74-year-old female with secondary myelofibrosis was initially treated with high-dose ruxolitinib.
She was switched to momelotinib due to transfusion-dependent anemia but developed significant peripheral neuropathy and arthralgias.
Despite dose reductions of momelotinib, the adverse effects persisted, leading to a switch back to low-dose ruxolitinib.
The reintroduction of ruxolitinib resulted in the maintenance of anemia control.
This case is the first reported instance of ruxolitinib rechallenge following momelotinib-related toxicity.
Clinical Implications
This case illustrates the potential for rechallenge of ruxolitinib after momelotinib toxicity.
Conclusion
This case suggests that reintroducing ruxolitinib after momelotinib-related toxicity may be an option for managing secondary myelofibrosis.
